CN109790160A - 吡啶并五元芳香环类化合物、其制备方法及用途 - Google Patents

吡啶并五元芳香环类化合物、其制备方法及用途 Download PDF

Info

Publication number
CN109790160A
CN109790160A CN201780055143.4A CN201780055143A CN109790160A CN 109790160 A CN109790160 A CN 109790160A CN 201780055143 A CN201780055143 A CN 201780055143A CN 109790160 A CN109790160 A CN 109790160A
Authority
CN
China
Prior art keywords
methyl
base
substituted
indolizine
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780055143.4A
Other languages
English (en)
Other versions
CN109790160B (zh
Inventor
陈旭星
耿美玉
江磊
陈奕
曹建华
蒋青云
沈倩倩
丁健
姚虞财
赵兆
熊远芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Haihe Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shanghai Haihe Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shanghai Haihe Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN109790160A publication Critical patent/CN109790160A/zh
Application granted granted Critical
Publication of CN109790160B publication Critical patent/CN109790160B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明提供了一种吡啶并五元芳香环类化合物、其制备方法及用途。本发明化合物对于野生型和/或突变型的EZH2有抑制作用，有望成为新型抗肿瘤或治疗自身免疫性疾病的药物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201780055143.4A 2016-09-07 2017-09-06 吡啶并五元芳香环类化合物、其制备方法及用途 Active CN109790160B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610807947.2 2016-09-07
CN201610807947 2016-09-07
PCT/CN2017/100747 WO2018045971A1 (zh) 2016-09-07 2017-09-06 吡啶并五元芳香环类化合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN109790160A true CN109790160A (zh) 2019-05-21
CN109790160B CN109790160B (zh) 2022-11-15

Family

ID=61561814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780055143.4A Active CN109790160B (zh) 2016-09-07 2017-09-06 吡啶并五元芳香环类化合物、其制备方法及用途

Country Status (12)

Country Link
US (1) US10968215B2 (zh)
EP (1) EP3524602A1 (zh)
JP (1) JP6816287B2 (zh)
KR (1) KR102351782B1 (zh)
CN (1) CN109790160B (zh)
AU (1) AU2017323112B2 (zh)
CA (1) CA3036114A1 (zh)
EA (1) EA038701B1 (zh)
MA (1) MA46199A (zh)
MX (1) MX2019002616A (zh)
WO (1) WO2018045971A1 (zh)
ZA (1) ZA201901827B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229151B (zh) 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
WO2020192650A1 (zh) 2019-03-25 2020-10-01 上海华汇拓医药科技有限公司 酰胺类化合物制备方法及其在医药领域的应用
WO2022188876A1 (zh) * 2021-03-11 2022-09-15 浙江大学 稠环杂环化合物及应用、含有其的药物组合物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2153818A (en) * 1983-12-21 1985-08-29 May & Baker Ltd Pyrazolopyridine derivatives
US20020002749A1 (en) * 2000-02-25 2002-01-10 Philippe Breton Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same
CN102365281A (zh) * 2009-03-31 2012-02-29 橘生药品工业株式会社 中氮茚衍生物及其医药用途
CN103987842A (zh) * 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
WO2016102493A1 (en) * 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318321T2 (de) * 2002-09-19 2008-12-11 Schering Corp. Pyrazolopyridine als hemmstoffe cyclin abhängiger kinasen
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
MX2009007302A (es) 2007-01-23 2009-07-15 Palau Pharma Sa Derivados de purina.
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
WO2012029942A1 (ja) 2010-09-03 2012-03-08 大日本住友製薬株式会社 環状アミド誘導体
WO2012075080A1 (en) * 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
JP2014511389A (ja) * 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
CA2854447A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
JP6373973B2 (ja) 2013-04-30 2018-08-15 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２エンハンサー阻害剤
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2015077193A1 (en) 2013-11-19 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2153818A (en) * 1983-12-21 1985-08-29 May & Baker Ltd Pyrazolopyridine derivatives
US20020002749A1 (en) * 2000-02-25 2002-01-10 Philippe Breton Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same
CN102365281A (zh) * 2009-03-31 2012-02-29 橘生药品工业株式会社 中氮茚衍生物及其医药用途
CN103987842A (zh) * 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
WO2016102493A1 (en) * 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴姗姗: "《STN》", 11 December 2020 *

Also Published As

Publication number Publication date
MA46199A (fr) 2019-07-17
AU2017323112B2 (en) 2020-11-26
AU2017323112A1 (en) 2019-03-28
US20190211010A1 (en) 2019-07-11
EA038701B1 (ru) 2021-10-07
EA201990645A1 (ru) 2019-08-30
US10968215B2 (en) 2021-04-06
EP3524602A1 (en) 2019-08-14
KR102351782B1 (ko) 2022-01-17
JP2019530740A (ja) 2019-10-24
ZA201901827B (en) 2021-07-28
KR20190077327A (ko) 2019-07-03
WO2018045971A1 (zh) 2018-03-15
CN109790160B (zh) 2022-11-15
CA3036114A1 (en) 2018-03-15
MX2019002616A (es) 2019-09-18
JP6816287B2 (ja) 2021-01-20

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN110156786B (zh) 嘧啶并环化合物及其制备方法和应用
WO2019158019A1 (zh) 嘧啶并环化合物及其制备方法和应用
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
CN110563722A (zh) 吡啶或哒嗪并环化合物及其应用
CN110964012B (zh) 一类稠杂环联芳基苄醇类化合物、制备方法和用途
WO2019120276A1 (zh) 嘧啶酮化合物及其应用
CN109790160A (zh) 吡啶并五元芳香环类化合物、其制备方法及用途
CN112409385A (zh) 氮杂芳基化合物及其应用
CN110655520A (zh) 嘧啶并环化合物及其制备方法和应用
CN111057048B (zh) 一类氨基吡嗪/吡啶类化合物、制备方法和用途
JP7451765B2 (ja) Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
JP7406008B2 (ja) Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
CN114907350A (zh) 一类含氮稠环类化合物、制备方法和用途
TW201904969A (zh) Ｃｋ２抑制劑，其組成物及方法
WO2022037691A1 (zh) 一类芳香环并内酰胺类化合物、其制备方法和用途
CN110229157B (zh) 嘧啶并五元芳香杂环类化合物、其制备方法及用途
CN110229151B (zh) 吲嗪类化合物、其制备方法及用途
CN115703799A (zh) 氮杂芳基化合物、其制备方法及应用
CN117561058A (zh) Cdk2抑制剂及其使用方法
CN114269753A (zh) 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
BR102019005173A2 (pt) Composto de pirido de anel aromático de cinco elementos, método de preparação do mesmo e uso do mesmo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 201203 Room 208, 103 Location, 6 Blocks, 421 Newton Road, China (Shanghai) Free Trade Experimental Area, Pudong New Area, Shanghai

Applicant after: Shanghai Haihe pharmaceutical research and Development Co.,Ltd.

Applicant after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Address before: 201203 Room 208, 103 Location, 6 Blocks, 421 Newton Road, China (Shanghai) Free Trade Experimental Area, Pudong New Area, Shanghai

Applicant before: SHANGHAI HAIHE PHARMACEUTICAL Co.,Ltd.

Applicant before: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20210528

Address after: Room 208, part 103, building 6, No. 421, Newton Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant after: Shanghai Haihe pharmaceutical research and Development Co.,Ltd.

Address before: Room 208, part 103, building 6, No. 421, Newton Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant before: Shanghai Haihe pharmaceutical research and Development Co.,Ltd.

Applicant before: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant